Blog

  • Nicola Blackwood – 2015 Parliamentary Question to the Attorney General

    Nicola Blackwood – 2015 Parliamentary Question to the Attorney General

    The below Parliamentary question was asked by Nicola Blackwood on 2015-11-26.

    To ask the Attorney General, how much of the Law Officers’ Departments funding allocated in the Spending Review 2015 will be for research and development expenditure up to 2020.

    Robert Buckland

    Spending Review 2015 set out settlements for departments and showed how the government will deliver on its priorities, eliminate the deficit, and deliver security and opportunity for working people.

    Final decisions on internal departmental funding allocations for future years, including for research and development, have not yet been made.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-26.

    To ask Her Majesty’s Government what percentage of eligible patients across England received access in (1) 2013, and (2) 2014, to the full range of NICE approved tumour genetic testing for (1) breast cancer in NHS tertiary centres, (2) breast cancer in NHS secondary centres, (3) colorectal cancer in tertiary centres, (4) colorectal cancer in secondary centres, (5) lung cancer in tertiary centres, (6) lung cancer in secondary centres, (7) melanoma in tertiary centres, and (8) melanoma in secondary centres.

    Lord Prior of Brampton

    All NHS England commissioned secondary and tertiary hospitals will be able to collect blood and/or tissue samples for the purpose of genetic testing, depending on the sampling technique required. The testing itself is however usually undertaken by commissioned genetic laboratories, which will typically serve a catchment area much greater than the hospital in which they are based. There will usually be recommended criteria in place to guide National Health Service referrals for genetic testing.

    In a small number of cases, usually for very rare conditions, a test may need to be sent away to a non commissioned laboratory, including some abroad and some falling within the private sector, to access expertise. Funding will, however, continue to be provided from NHS budgets.

    The United Kingdom is also leading the world by using cutting edge technology in the form of whole genome sequencing to transform healthcare and health research. The Prime Minister launched the 100,000 Genomes Project to bring the benefits of genome sequencing to NHS patients. The Project will sequence 100,000 whole human genomes of NHS patients with cancer or a rare disease by the end of 2017. Eleven Genomic Medicine Centres have been established across the country and are recruiting patients to this landmark project. Otherwise, NHS England does not hold data on private or self-funded care or testing commissioned from either NHS or third party laboratories.

    Information on the percentage of eligible patients who received access to genetic testing is not held by NHS England. Due to data protection requirements, detailed data on the reasons for referral for specific tests are not currently aggregated at national level.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-26.

    To ask Her Majesty’s Government what percentage of NHS secondary care centres do not provide tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

    Lord Prior of Brampton

    All NHS England commissioned secondary and tertiary hospitals will be able to collect blood and/or tissue samples for the purpose of genetic testing, depending on the sampling technique required. The testing itself is however usually undertaken by commissioned genetic laboratories, which will typically serve a catchment area much greater than the hospital in which they are based. There will usually be recommended criteria in place to guide National Health Service referrals for genetic testing.

    In a small number of cases, usually for very rare conditions, a test may need to be sent away to a non commissioned laboratory, including some abroad and some falling within the private sector, to access expertise. Funding will, however, continue to be provided from NHS budgets.

    The United Kingdom is also leading the world by using cutting edge technology in the form of whole genome sequencing to transform healthcare and health research. The Prime Minister launched the 100,000 Genomes Project to bring the benefits of genome sequencing to NHS patients. The Project will sequence 100,000 whole human genomes of NHS patients with cancer or a rare disease by the end of 2017. Eleven Genomic Medicine Centres have been established across the country and are recruiting patients to this landmark project. Otherwise, NHS England does not hold data on private or self-funded care or testing commissioned from either NHS or third party laboratories.

    Information on the percentage of eligible patients who received access to genetic testing is not held by NHS England. Due to data protection requirements, detailed data on the reasons for referral for specific tests are not currently aggregated at national level.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-26.

    To ask Her Majesty’s Government what percentage of NHS secondary care centres provide third-party tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

    Lord Prior of Brampton

    All NHS England commissioned secondary and tertiary hospitals will be able to collect blood and/or tissue samples for the purpose of genetic testing, depending on the sampling technique required. The testing itself is however usually undertaken by commissioned genetic laboratories, which will typically serve a catchment area much greater than the hospital in which they are based. There will usually be recommended criteria in place to guide National Health Service referrals for genetic testing.

    In a small number of cases, usually for very rare conditions, a test may need to be sent away to a non commissioned laboratory, including some abroad and some falling within the private sector, to access expertise. Funding will, however, continue to be provided from NHS budgets.

    The United Kingdom is also leading the world by using cutting edge technology in the form of whole genome sequencing to transform healthcare and health research. The Prime Minister launched the 100,000 Genomes Project to bring the benefits of genome sequencing to NHS patients. The Project will sequence 100,000 whole human genomes of NHS patients with cancer or a rare disease by the end of 2017. Eleven Genomic Medicine Centres have been established across the country and are recruiting patients to this landmark project. Otherwise, NHS England does not hold data on private or self-funded care or testing commissioned from either NHS or third party laboratories.

    Information on the percentage of eligible patients who received access to genetic testing is not held by NHS England. Due to data protection requirements, detailed data on the reasons for referral for specific tests are not currently aggregated at national level.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-26.

    To ask Her Majesty’s Government what percentage of NHS secondary care centres provide in-house tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

    Lord Prior of Brampton

    All NHS England commissioned secondary and tertiary hospitals will be able to collect blood and/or tissue samples for the purpose of genetic testing, depending on the sampling technique required. The testing itself is however usually undertaken by commissioned genetic laboratories, which will typically serve a catchment area much greater than the hospital in which they are based. There will usually be recommended criteria in place to guide National Health Service referrals for genetic testing.

    In a small number of cases, usually for very rare conditions, a test may need to be sent away to a non commissioned laboratory, including some abroad and some falling within the private sector, to access expertise. Funding will, however, continue to be provided from NHS budgets.

    The United Kingdom is also leading the world by using cutting edge technology in the form of whole genome sequencing to transform healthcare and health research. The Prime Minister launched the 100,000 Genomes Project to bring the benefits of genome sequencing to NHS patients. The Project will sequence 100,000 whole human genomes of NHS patients with cancer or a rare disease by the end of 2017. Eleven Genomic Medicine Centres have been established across the country and are recruiting patients to this landmark project. Otherwise, NHS England does not hold data on private or self-funded care or testing commissioned from either NHS or third party laboratories.

    Information on the percentage of eligible patients who received access to genetic testing is not held by NHS England. Due to data protection requirements, detailed data on the reasons for referral for specific tests are not currently aggregated at national level.

  • Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    Lord Freyberg – 2015 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Lord Freyberg on 2015-11-26.

    To ask Her Majesty’s Government what percentage of NHS tertiary care centres provide in-house tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

    Lord Prior of Brampton

    All NHS England commissioned secondary and tertiary hospitals will be able to collect blood and/or tissue samples for the purpose of genetic testing, depending on the sampling technique required. The testing itself is however usually undertaken by commissioned genetic laboratories, which will typically serve a catchment area much greater than the hospital in which they are based. There will usually be recommended criteria in place to guide National Health Service referrals for genetic testing.

    In a small number of cases, usually for very rare conditions, a test may need to be sent away to a non commissioned laboratory, including some abroad and some falling within the private sector, to access expertise. Funding will, however, continue to be provided from NHS budgets.

    The United Kingdom is also leading the world by using cutting edge technology in the form of whole genome sequencing to transform healthcare and health research. The Prime Minister launched the 100,000 Genomes Project to bring the benefits of genome sequencing to NHS patients. The Project will sequence 100,000 whole human genomes of NHS patients with cancer or a rare disease by the end of 2017. Eleven Genomic Medicine Centres have been established across the country and are recruiting patients to this landmark project. Otherwise, NHS England does not hold data on private or self-funded care or testing commissioned from either NHS or third party laboratories.

    Information on the percentage of eligible patients who received access to genetic testing is not held by NHS England. Due to data protection requirements, detailed data on the reasons for referral for specific tests are not currently aggregated at national level.

  • Lord Marlesford – 2015 Parliamentary Question to the HM Treasury

    Lord Marlesford – 2015 Parliamentary Question to the HM Treasury

    The below Parliamentary question was asked by Lord Marlesford on 2015-11-26.

    To ask Her Majesty’s Government why they have increased the Resource Departmental Expenditure Limit for International Development by 16.1 per cent between 2017–18 and 2018–19, as per Table 1A of the Spending Review and Autumn Statement 2015.

    Lord O’Neill of Gatley

    Total departmental expenditure limits (TDEL) for the Department for International Development (DFID) are set on the basis of forecast Gross National Income (GNI) growth to enable the Government to meet the commitment to spend 0.7 per cent of GNI on official development assistance (ODA). Budgets also take into account assumptions for non-budgetary spend on ODA such as the UK’s share of EU ODA expenditure. As a result, DFID’s total DEL budget will increase by 8.5 per cent between 17/18 and 19/20.

    The split between capital and resource DEL is set to help manage pressures such as capital contributions to multilateral development banks.

  • Baroness King of Bow – 2015 Parliamentary Question to the Department for Communities and Local Government

    Baroness King of Bow – 2015 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by Baroness King of Bow on 2015-11-26.

    To ask Her Majesty’s Government what action they have taken in response to the Homes and Communities Agency’s decision to downgrade Circle Housing Group’s governance rating from G1 to G3 following its failure to manage properly its Repair and Maintenance Contract with the Kier Group.

    Baroness Williams of Trafford

    The Social Housing Regulator has a clear regulatory framework which it used in this case. As is normal practice the Social Housing Regulator is working closely with Circle as it continues to recover its repair service and improves its governance. The Regulator currently has sufficient assurance of Circle’s intention to address the issues and its progress in doing so, such that the Regulator considers it does not need to apply enforcement powers at this point. The Regulator will of course continue to examine new information that comes to light.

  • Baroness King of Bow – 2015 Parliamentary Question to the Department for Communities and Local Government

    Baroness King of Bow – 2015 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by Baroness King of Bow on 2015-11-26.

    To ask Her Majesty’s Government how much of the £150 million funding made available for the regeneration of local authority housing estates has been made available to each of the successful schemes.

    Baroness Williams of Trafford

    Shortlisted schemes are currently undergoing due diligence. Subject to this, we expect contracts to be signed in this financial year and the full £150 million to be committed. The final amount for each scheme is yet to be confirmed.

  • Baroness King of Bow – 2015 Parliamentary Question to the Department for Communities and Local Government

    Baroness King of Bow – 2015 Parliamentary Question to the Department for Communities and Local Government

    The below Parliamentary question was asked by Baroness King of Bow on 2015-11-26.

    To ask Her Majesty’s Government whether the research by Savills into the opportunities for estate regeneration, commissioned by the Number 10 Policy Unit, was contracted through an open tendering process.

    Baroness Williams of Trafford

    The research into the opportunities for estate regeneration across London was a result of general discussions with Savills and the Number 10 Policy Unit, which led to an approach by Savills to complete this work. The Number 10 Policy Unit commissioned this work as a single tender.